Compare CLDX & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDX | EXPO |
|---|---|---|
| Founded | N/A | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 1995 | 1996 |
| Metric | CLDX | EXPO |
|---|---|---|
| Price | $42.66 | $66.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $46.60 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 963.5K | 492.9K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.19 |
| Revenue | $12,743,000.00 | ★ $582,014,000.00 |
| Revenue This Year | $111.39 | $12.75 |
| Revenue Next Year | $235.85 | $8.50 |
| P/E Ratio | ★ N/A | $56.39 |
| Revenue Growth | ★ 87.78 | 4.21 |
| 52 Week Low | $20.37 | $51.91 |
| 52 Week High | $45.14 | $81.95 |
| Indicator | CLDX | EXPO |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 54.51 |
| Support Level | $28.51 | $64.38 |
| Resistance Level | N/A | $69.27 |
| Average True Range (ATR) | 1.71 | 2.08 |
| MACD | 0.24 | -0.12 |
| Stochastic Oscillator | 72.23 | 49.66 |
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.